Put Options on ARVN on 12/6/2021

Arvinas, Inc. (ARVN), a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. 

Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer.

The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Bayer AG, and Insilico Medicine, Inc. 

Shares have fallen below a support level and lower share prices are expected for this stock.

Last Trade:  $74.44

Trading Range: $25.00 to $108.46

We will be trading January Put options

Trade Buy 1 January $75.00 Put at $6.00 For a net debit of $6.00 Profit/Loss Analysis Breakeven at $69.00 Maximum profit is unbounded Maximum loss is ($600.00) at strike of $75.00 Closing Summary Sold 1 January $75.00 Put at $11.20

Position closed on 1/14/2022 at price of $11.20 with a 86.67% gain in 39 days.

Updates

1/14/2022 11:23:05 AM

ARVN $75 Put option closed

Back to Portfolio